BioRestorative Therapies Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
Analyst Coverage
2analysts covering
FY EPS (est.)
-$0.66next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Earnings Release | 12 Nov 2026 |
| Phase 2 Topline Data for BRTX-100 | 31 May 2027 |
Monitoring Framework
Key Performance Indicators
BRTX-100 Phase 2 Trial Dosing Completion Quarterly100.0Target: 100% (105 subjects dosed)
Oswestry Disability Index (ODI) Improvement Annually52.0Target: >=30% improvement in at least 50% of patients
Visual Analog Scale (VAS) Pain Reduction AnnuallyTarget: >=30% reduction in at least 50% of patients
Cash and Cash Equivalents Quarterly3.1MTarget: Sufficient to fund Phase 3 enabling activities
Watch Items
- Phase 3 IND Amendment SubmissionTrigger: Submission targeted for H2 2026Action: Monitor SEC filings and press releases for FDA clearance of the Phase 3 IND amendment.
- Nasdaq Minimum Bid Price ComplianceTrigger: Stock price below $1.00 (Notice received March 26, 2026)Action: Track stock price and potential corporate actions (e.g., reverse stock split) to regain compliance.
- Going Concern Risk and Cash BurnTrigger: Operating cash outflow of $3.81M in Q1 2026 vs $3.11M cash balanceAction: Evaluate upcoming capital raises, warrant exercises, or strategic partnerships to extend runway.
Research as of 20 Jun 2026